Two different dosing regimens demonstrated efficacy with one showing a better profile; No hospitalizations or severe cases of COVID-19 in participants treated with AZD1222
JOHANNESBURG, SA: Today marks an important step in turning the corner on the pandemic and getting things back to normal. Following the positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil, which showed the vaccine was highly effective in preventing COVID-19, we are confident that our united response, across the scientific community, industry, organizations, and governments, will make significant inroads in curbing the COVID-19 pandemic that has continued to claim thousands of lives every day in Africa and across the globe. We will continue to work hard to honor our commitment to make the vaccine available in a fair and equitable manner as rapidly as possible, following robust regulatory approval and meet stringent efficacy and safety standards. It is a great day for innovation and for inclusion, an exciting moment for human health.” said, Barbara Nel Country President African Cluster: South Africa, Sub Saharan Africa, French Speaking Africa
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Sign me up for the newsletter!
Notify me of follow-up comments by email.
Notify me of new posts by email.
2014 The Global Indian New Network (TGINN)